Page last updated: 2024-09-04

dihydroguaiaretic acid and Liver Steatosis

dihydroguaiaretic acid has been researched along with Liver Steatosis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Choi, YJ; Je, YT; Lee, BH; Lee, KY; Park, HJ; Park, S; Park, SJ; Shin, KJ; Sim, WC; Sung, SH; Yin, HQ1
Hwang, JK; Kim, D; Kim, KJ; Lee, KE; Lee, MS1

Other Studies

2 other study(ies) available for dihydroguaiaretic acid and Liver Steatosis

ArticleYear
LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver.
    Biochemical pharmacology, 2014, Aug-15, Volume: 90, Issue:4

    Topics: Animals; Base Sequence; Cell Line, Tumor; Diet, High-Fat; DNA Primers; Fatty Liver; Guaiacol; Humans; Lignans; Lipogenesis; Liver X Receptors; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Non-alcoholic Fatty Liver Disease; Orphan Nuclear Receptors

2014
meso-Dihydroguaiaretic acid inhibits hepatic lipid accumulation by activating AMP-activated protein kinase in human HepG2 cells.
    Biological & pharmaceutical bulletin, 2011, Volume: 34, Issue:10

    Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Cell Culture Techniques; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyslipidemias; Enzyme Activation; Enzyme Inhibitors; Fatty Liver; Guaiacol; Hep G2 Cells; Humans; Hypolipidemic Agents; Insulin Resistance; Lignans; Lipid Metabolism; Liver; Molecular Targeted Therapy; Myristica; Non-alcoholic Fatty Liver Disease; Phosphorylation; Phytotherapy; Plant Extracts; Pyrazoles; Pyrimidines

2011